http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
褥瘡에 대한 治驗 1 例 報告 : an External Therapy with ASTRAGALI RADIX Powder
허영란,문성호,최중길 대한본초학회 2000 大韓本草學會誌 Vol.15 No.2
Pressure sore is the ulceration and necrosis of the skin and underlying tissue usually occurred on the bony prominence of the body after prolonged or repeated pressure. Recently, the incidence of the pressure sore has been increased due to the development of the industry, increased number of the traffic accident and the cerebrovascular accident. Authors reviewed 4 sites of a patient who had received external application with ASTRAGALI RADIX powder for the pressure sore. Pressure sore of the patient was improved in about 4 months. ASTRAGALI RADIX has two effects: promoting tissue regeneration(生?) and evacuating the pus by administering tonics(????). So ASTRAGALI RADIX is proper for the external application of the pressure sore.
고강도 콘크리트(80MPa이상)를 이용한 콘크리트충전강관구조 적용을 위한 기초물성 연구
이장환,강용학,정근호,김진호,정상진,최문식 대한건축학회 2003 대한건축학회 학술발표대회 논문집 - 계획계/구조계 Vol.23 No.2
One of the most important reasons that CFT is used in many conditions is by using that we can achieve the effect, which reduce the section of the member. This research purpose to find the most ideal composition, which is achieved by the investigation in the concrete's property of matter like ability of Slump, Slump Flow, Air content, Bleeding, and Settlement when the high strength of concrete which is over 80MPa is used m the CFT column.
서중조건하에서의 콘크리트 충전 강관 기둥의 시공을 위한 실험적 연구
이장환,강용학,정근호,김진호,최문식,정상진 대한건축학회 2003 대한건축학회 학술발표대회 논문집 - 계획계/구조계 Vol.23 No.1(구조계)
The basic Physical properties, Slump, Slump flow, Air content, Bleeding, and Settlement of concrete was investigated to test Characteristic of Setting and to evaluate the relation between Model specimen and Heat of hydration for construction Over the High Temperature(CFT). The objective of this study is to take the partial core after the cementation of Model specimen, test the compression intensity and analyze the relation to Test piece.
CFT구조용 초고강도 충전 콘크리트의 현장 적용을 위한 실험적 연구
이장환,남정민,정근호,김진호,정상진,최문식 대한건축학회 2004 대한건축학회 학술발표대회 논문집 - 계획계/구조계 Vol.24 No.1(구조계)
Due to social problems such as the increasing of land price and the expanding of city, buildings require more complex and bigger components and structure. However, the complex and massive building projects need new technology to solve effect of local buckling and the needs for more space. Hence, Concrete Filled Tube Steel (CFT), the tube steel to hold concrete during pouring and curing of concrete procedure, which helps to reduce local buckling and space, was developed. Most researches on CFT might not be focused on the characteristic of concrete filled in tube but structural analysis. However, it is the essential factor to increase the strength of concrete on CFT for having efficient results. Therefore, this paper will describe how to apply CFT into the construction site through examining High Strength Concrete (800kg/cm2), the strength of core, and bleeding during pouring strategy.
손영준,송인명,양동일,정근호,정상진,최문식 대한건축학회 2004 대한건축학회 학술발표대회 논문집 - 계획계/구조계 Vol.24 No.1(구조계)
The column for Steel Framed Reinforced Concrete Structure (SFRCS) and the column for Reinforced Concrete Structure (RCS) could be the most common building structure. The increasing of the need for massive space hasaffected the size of building components for supporting the massive structure. However, the changing of components size makes inefficient space of building. Hence, to meet the need for acquiring efficient space comparing the budget and cost the new structure method, Concrete Filled Tube Steel (CFT), was developed. CFT is the structure for which steel tube instead of other materials such as wood for holding concrete is used. The most benefit of this one is to help in reducing the size of the building components and local buckling because of tube steel holding concrete. For this reason, this research will examine the probability of applying CFT on construction sites by using the concrete (800kg/cm2) especially for CFT through the data from the real size mock-up.
Jung-Hye Choi,In-Soon Kim,Il-Young Choi,Myung-Ju Ahn,Seock-Ah Im,Bong-Seog Kim,Ho-Suk Oh,Heung Woo Lee,Yeung Chul Mun,Chu-Myung Seong,Soon Nam Lee,Young-Yeul Lee 대한암학회 2003 Cancer Research and Treatment Vol.35 No.3
Purpose: Gemcitabine and 5-fluorouracil (5-FU) are twocompounds with reproducible activity against advancedpancreatic carcinomas. To evaluate the activity and feasibilityof this combination chemotherapy, a multi-institutionalphase II study was performed.Materials and Methods: Twenty patients (maleခfemale15ခ5, median age: 60.5 years), with histologically verifiedlocally advanced or metastatic pancreatic carcinomas,were enrolled between April 2000 and March 2002.Gemcitabine was administered by intravenous injectionat the doses of 1,000 mg/m2 on days 1, 8 and 15, and5-FU 800 mg/m2/day, was given by continuous intravenousinfusion on days 1~5. The treatment was repeatedevery 4 weeks. The clinical benefit response (CBR) wasa composite of the pain, Karnofsky performance statusand body weight change measurement.Results: Nineteen of the twenty patients were assessablefor response. The median follow-up duration was 4.6months (0.4~15.2 months). Five patients achieved a partialresponse and eight a stable disease. The overall responserate was 25.0%. The CBR was assessable in 12 patients.The overall CBR was 41.7% (5/12). The median survivalof all the patients was 8.0 months. Grade 3~4 toxicitiesincluded neutropenia (9.3%) and thrombocytopenia (5.3%).Conclusion: This study suggested that gemcitabine,combined with infusional 5-FU, was well tolerated, andproduced modest antitumor activity and symptomaticrelief in advanced pancreatic cancer patients. (Cancer Res Treat. 2003;35:213-217)
Immunological Monitoring of Urinary Aflatoxins and Estimation of Liver Cancer Incidence in Koreans
Choi, Mun-Jung,You, Young-Chan,Kim, Hyung-Sik,Lee, Byung-Mu Korean Society for Biochemistry and Molecular Biol 1996 Journal of biochemistry and molecular biology Vol.29 No.2
Polyclonal antiserum R101 against aflatoxin $B_1$ ($AFB_1$) was raised in New Zealand white rabbits after injection of bovine serum albumin-$AFB_1$ conjugate. Competitive ELISA (enzyme linked immuno-sorbent assay) demonstrated that antiserum R101 has the highest binding for $AFB_1$ (50% inhibition at 170 fmol) and aflatoxicol II (50% inhibition at 112 fmol). It also reacts with other aflatoxins such as $AFB_2$, $AFG_1$, $AFG_2$, and aflatoxin metabolites ($AFM_1$, $AFM_2$, $AFP_1$, and $AFQ_1$), but it does not cross-react with $AFG_2a$. Using this antiserum, aflatoxins were quantitated in 100 urine samples of undergraduate students at the College of Pharmacy, Sung Kyun Kwan University, Republic of Korea. By ELISA, $AFB_1$ and its metabolites were detected in human urine samples (N=100, male=89, female=11, ages=20~31 yrs) with a range of 1.4~200.6 ng/kg/day (mean$\pm$SD=$18.11{\pm}33.01\;ng\;AFB_1/kg/day$ in males, $3.82{\pm}2.65\;ng/kg/day$ in females). Assuming that urinary excretion is about 7.6% of $AFB_1$ intake (Groopman et al., 1992), we estimated that Koreans were daily exposed to a total dietary $AFB_1$ of $240.20{\pm}438.67\;ng/kg/day$ in males and $50.35{\pm}29.88\;ng/kg/day$ in females, respectively. When the human monitoring data was applied to a linear regression model of Y=21.67X-10.04 {Y=liver cancer incidence per 100,000, X=Log $AFB_1$ intake (ng/kg/day), r=0.99} developed from previously reported epidemiological data, calculated liver cancer incidences attributed to $AFB_1$ exposure were 41.56/100,000 in males and 26.84/100,000 in females. The incidences were similarly correlated with liver cancer mortality rates of 43.43/100,000 in males and 11.23/100,000 in females in Korea. These results suggest that aflatoxin exposure may be an important risk factor for the high incidence of liver cancer in Korea.
Choi, Jung Kyu,Lee, Jae Hee,Lee, Seung Tae,Choi, Mun Hwan,Gong, Seung Pyo,Lee, Eun Ju,Lim, Jeong Mook Asian Australasian Association of Animal Productio 2007 Animal Bioscience Vol.20 No.8
This study was conducted to improve efficiency of a follicle culture system without reducing developmental competence of intrafollicular oocytes. Preantral follicles (100 to $125{\mu}m$ in diameter) of F1 hybrid (B6CBAF1) mice were cultured singly for 216 h in modified ${\alpha}$-MEM-glutamax medium, to which 2.5 IU/ml hCG and epidermal growth factor was added 16 h prior to the end of culture. Medium change was either performed three times (54 h interval), twice (72 h interval), once (108 h interval), or not at all (216 h interval). Maturation (progression to the metaphase II stage) of intrafollicular oocytes was detected from 4 days after culture in the three-times change treatment, while all treatments yielded mature oocytes from day 5 of culture. Compared with the three-times change, decreasing the change frequency to once did not reduce the capacity to begin maturation (germinal vesicle breakdown of 82 to 86%), to mature (78 to 79%) and to develop into blastocysts after parthenogenetic activation (29 to 32%). Morphological parameters were similar among these treatments. Except for the no medium change treatment, similar colony-forming activity of inner cell mass cells after culturing of blastocysts in leukemia inhibitory factor-containing medium was detected, while the morphology of the colony-forming cells deteriorated in the change-once treatment compared with the change twice or three-times. In conclusion, the efficiency of the preantral follicle culture system could be improved by reducing frequency of medium change up to a 72 h interval (three times in total 216 h culture) without decreasing developmental competence of oocytes.
Choi, Jin-Young,Chang, Yoon-Jung,Hong, Young-Seon,Heo, Dae-Seog,Kim, Sam-Yong,Lee, Jung-Lim,Choi, Jong-Soo,Kang, Ki-Mun,Kim, Si-Young,Jeong, Hyun-Sik,Lee, Chang-Geol,Choi, Youn-Seon,Lim, Ho-Yeong,Yun, Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.4
Objectives: To investigate in depth the use of complementary and alternative medicines (CAMs) by cancer patients at the end-of-life (EOL) and how they communicate with physicians about them. Design and location: In 17 hospitals in Korea between January and December 2004 we identified 4,042 families of cancer patients. Results: The prevalence of CAM use among cancer patients at the EOL was 37.0%, and 93.1% had used pharmacologic types of agents. The most frequent motive for CAM use was the recommendation of friends or a close relative (53.4%) or a physician (1.6%). Only 42.5% discussed CAM use with their physicians. Satisfaction with CAMS was recalled for 37.1%. The most common reason given for that satisfaction was improvement of emotional or physical well-being, while ineffectiveness was the most common reason given for dissatisfaction. The average cost of CAM during the last month of life was $US 900. CAM use was associated with longer disease periods, primary cancers other than liver, biliary, and pancreatic, and need of support from physicians or religion. Conclusions: CAM use among cancer patients at the EOL was common, not discussed with physicians, and associated with expectation of cure. Expectations were generally unmet while the treatments were a financial burden. Further studies evaluating the effects of CAM at the EOL and factors that enhance communication with the physician are needed.